Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) Market Outlook

Thelansis’s “Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Recurrent Low-Grade Serous Ovarian Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) Overview

Ovarian cancer is a type of malignancy that occurs in women. The majority of ovarian cancers, up to 90%, originate from the epithelial cells of the ovary. These cancers can be further classified into subtypes based on their histological and immunohistochemical characteristics, with the most common subtypes being high-grade serous (70%), low-grade serous, high-grade endometrioid, low-grade endometrioid, clear cell, and mucinous carcinomas. Low-grade serous carcinoma of the ovary or peritoneum (LGSC) is a rare subtype, accounting for between 5 and 8% of all ovarian carcinomas. LGSC can develop from a precursor lesion known as a serous borderline ovarian tumor (SBOT) or a de novo malignancy in the ovary or peritoneum. Patients with LGSC may present with non-specific symptoms such as abdominal discomfort, bloating, dyspnea, dyspepsia, and changes in bowel movement patterns. Alternatively, it may arise from the malignant transformation of a borderline ovarian tumor. LGSOC is characterized by being WT1 positive (95%), p53 wild-type (90%), ER-positive (57%), and PR positive (78%). Additionally, LGSOC typically presents with activating mutations in the RAS-RAF-MEK-ERK pathway. The neoplasm usually appears as a solid cystic mass involving the ovarian surface and parenchyma, with sizes ranging from 0.2 cm to over 20 cm. Bilaterality is present in approximately 50% of cases. The contents of the tumor are typically serosanguineous or watery and straw-coloured and less frequently mucinous. Patients with low-grade serous carcinoma tend to be younger than those with high-grade tumors, with a mean age of 45–57 years and 55–65 years, respectively.

• In China, the ovarian cancer incidence rate was estimated to be 4.2 per 100,000.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: